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Genomic instability plays a pathological role in various malignan-cies, including acute myeloid leukemia (AML), and thus repre-sents a potential therapeutic target. Recent studies demonstrate
that SIRT6, a NAD+-dependent nuclear deacetylase, functions as
genome-guardian by preserving DNA integrity in different tumor cells.
Here, we demonstrate that also CD34+ blasts from AML patients show
ongoing DNA damage and SIRT6 overexpression. Indeed, we identified
a poor-prognostic subset of patients, with widespread instability, which
relies on SIRT6 to compensate for DNA-replication stress. As a result,
SIRT6 depletion compromises the ability of leukemia cells to repair DNA
double-strand breaks that, in turn, increases their sensitivity to daunoru-
bicin and Ara-C, both in vitro and in vivo. In contrast, low SIRT6 levels
observed in normal CD34+ hematopoietic progenitors explain their
weaker sensitivity to genotoxic stress. Intriguingly, we have identified
DNA-PKcs and CtIP deacetylation as crucial for SIRT6-mediated DNA
repair. Together, our data suggest that inactivation of SIRT6 in leukemia
cells leads to disruption of DNA-repair mechanisms, genomic instability
and aggressive AML. This synthetic lethal approach, enhancing DNA
damage while concomitantly blocking repair responses, provides the
rationale for the clinical evaluation of SIRT6 modulators in the treatment
of leukemia.
Depletion of SIRT6 enzymatic activity 
increases acute myeloid leukemia cells’ 
vulnerability  to DNA-damaging agents 
Antonia Cagnetta,1,2* Debora Soncini,1* Stefania Orecchioni,3
Giovanna Talarico,3 Paola Minetto,1 Fabio Guolo,1 Veronica Retali,1,2
Nicoletta Colombo,1 Enrico Carminati,1 Marino Clavio,1,2 Maurizio Miglino,1,2
Micaela Bergamaschi,1 Aimable Nahimana,4 Michel Duchosal,4 Katia Todoerti,5
Antonino Neri,6,7 Mario Passalacqua,8 Santina Bruzzone,8 Alessio Nencioni,2,9
Francesco Bertolini,3 Marco Gobbi,1,2 Roberto M. Lemoli1,2** and Michele Cea1,2** 
1Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova,
Italy; 2Hematology Unit, Policlinico San Martino, Genova, Italy; 3European Institute of
Oncology, Milan, Italy; 4Service and Central Laboratory of Hematology, University
Hospital of Lausanne, Switzerland; 5Laboratory of Pre-Clinical and Translational
Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture,
Potenza, Italy; 6Department of Oncology and Hemato-Oncology, University of Milan, Italy;
7Hematology Unit, Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy;
8Department of Experimental Medicine, University of Genova, Italy and 9Department of
Internal Medicine, University of Genova, Italy
*AC and DS are co-first authors. **MC and RML are co-senior authors
ABSTRACT
Introduction
Acute myeloid leukemia (AML) is an aggressive form of cancer with an estimated
incidence in Europe of 3-5 cases per 100,000 people.1,2 It is a highly heterogeneous
disease, both biologically and clinically, with variable prognosis. Despite the
improvement in our understanding of the biology of AML, the last 20 years have
seen no improvement in treatment.3,4 Chemotherapy remains the backbone of ther-
apy whereas stem cell transplantation is mainly offered to young patients (age <60
years).5,6  Therefore, the majority of AML patients (e.g. elderly patients), who are
often unable to tolerate intensive treatments, face a particularly poor prognosis.7
Thus, there is an urgent need to overcome biological mechanisms underlying drug
resistance in AML, to enhance the efficacy of existing treatments, and to facilitate
the design of novel approaches. Several studies have shown that AML oncogenes,
such as MLL fusions, N-RAS, and FLT3-ITD can lead to DNA damage accumulation
by promoting replication and oxidative stress.8-12 In these cases, upregulation of
DNA damage response (DDR) provides AML cells with a selective survival advan-
tage, but also creates room for synthetic lethal interven-
tions.  
Sirtuins are a family of NAD+-dependent deacetylase
modifying enzymes that are up-regulated in a wide range
of tumors and have a central role in integrating growth sig-
nals that regulate a number of cellular pathways including
metabolism, genome stability, cell proliferation, and sur-
vival.13,14 Recently, we have demonstrated that multiple
myeloma (MM) cells exhibit constitutive overexpression
of SIRT6, a member of this family with a critical role for
DNA damage repair, which provides implications for both
tumorigenesis and treatment of this tumor.15 Here, we
show that SIRT6 has biological relevance also in AML
being frequently up-regulated in tumor cells compared
with normal CD34+ hematopoietic progenitors.
Importantly, such a feature is associated with a signature
of chromosomal instability (CIN) which in turn confers
poor prognosis to a subgroup of AML patients.16
Consistent with its observed role, SIRT6 loss unleashes
genomic instability thus triggering hypersensitivity to clin-
ically used DNA-damaging agents, including daunorubicin
(DNR) and cytarabine (ARA-C), both in vitro and in vivo.
Mechanistically, SIRT6 binds DNA damage sites, recruits
and activates, by deacetylation, DNA-PKcs and CtIP pro-
moting overall DNA repair. 
Taken together, our findings suggest that hematologic
cancers, including AML, have constitutive ongoing DNA
damage as well as a steadily activated DNA repair
response. As a result, strategies aimed at shifting the bal-
ance towards high DNA damage and reduced DNA repair
by SIRT6 inhibition can decrease tumor growth and may
benefit patients with otherwise unfavorable outcomes. 
Methods 
For a more detailed description of the methods used, see the
Online Supplementary Appendix. 
Cell lines and reagents
The AML cell lines U937, MOLM-14, MV4-11, HL60, HEL,
THP-1, NOMO-1, OCI-AML2, OCI-AML3 and NB4 were provid-
ed by collaborators or were purchased from ATCC or DSMZ
(Braunschweig, Germany). All cell lines were cultured in RPMI-
1640 medium containing 10% FBS (GIBCO, Life Technologies,
Carlsbad, CA, USA), 2 μM l−1 glutamine, 100 U mL−1 penicillin,
and 100 μg ml−1 streptomycin (GIBCO, Life Technologies,
Carlsbad, CA, USA). The 293T cell line was purchased from
ATCC and cultured in DMEM containing 10% FBS (GIBCO, Life
Technologies, Carlsbad, CA, USA), 2 μM l−1 glutamine, 
100 U mL−1 penicillin, and 100 μg mL−1 streptomycin (GIBCO,
Life Technologies, Carlsbad, CA, USA). Daunorubicin (DNR) and
cytarabine (ARA-C) were purchased from Selleck Chemicals LLC
(Houston, TX, USA) and Sigma-Aldrich (St. Louis, MO, USA),
respectively; SIRT6 chemical inhibitor [2,4-dioxo-N-(4-(pyridin-3-
yloxyphenyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide,
henceforth named compound  1] was obtained from MolPort
(Riga, Latvia).
Primary cell isolation from patient samples
All studies involving human samples were performed after
informed consent under institutional review board protocols of
San Martino Hospital (Genova, Italy). De-identified samples were
utilized. Patient AML cells (n=20) were obtained from bone mar-
row (BM) samples with a high disease load (>90% CD34+ blasts
in the marrow) and mononuclear cells were isolated by Ficoll-
Hypaque gradient separation as described previously.17 Normal
mononuclear cells (MNCs) were isolated from BM healthy donors
by Ficoll-Hypaque centrifugation. In some experiments, normal
peripheral blood (PB) MNCs were processed by MiniMacs high-
gradient magnetic separation column (Miltenyi Biotec, Bergisch
Gladbach, Germany) to obtain highly purified CD34+ cells. Cells
were either used immediately for viability assays or for mRNA
isolation, or stored at −80°C in medium containing 50% FBS and
10% DMSO.
Statistical analyses
All data are shown as means±Standard Deviation (s.d.). Student
t-test was used to compare two experimental groups using Graph-
Pad Prism software. Correlation of SIRT6 expression with disease
progression and overall survival (OS) were measured using the
Kaplan-Meier method, and the  log rank test was used for group
comparison. P<0.05 was considered statistically significant.
Results
SIRT6 is consistently over-expressed in CD34+ blasts of
AML patients
SIRT6 is a chromatin remodeling-deacetylase involved
in tumorigenesis.15,18-21 In order to explore its function in
AML, we tested a panel of leukemia cell lines and patient-
derived tumor cells to evaluate the presence of this pro-
tein. All tested tumor cells showed higher SIRT6 staining
than normal cells, regardless of their genetic landscape
(Figure 1A). Notably, immunofluorescence analysis of
selected AML cell lines (Figure 1B) confirmed a prominent,
although not restricted, nuclear localization of this pro-
tein, as already reported in different tumors.15,22-24  Next,
SIRT6 expression was further analyzed by querying pub-
licly available data sets.25,26 A significantly higher SIRT6
mRNA level was found in tumor samples (n=300) com-
pared with PB and BM normal hematopoietic and stem
cells, including CD34+ stem/progenitor cells (HSPCs),
more primitive CD34+ CD38– cells and unselected
mononuclear cells (from BM or PB) (Figure 1C).
Correlative analysis of SIRT6 levels with clinico-patholog-
ical features suggested significant association between
SIRT6 expression and French-American-British (FAB) clas-
sification (Online Supplementary Figure S1A). Indeed,
among AML groups, SIRT6 was higher in FAB M0 and M5
whilst the FAB M6 subgroup was enriched in patients
with SIRT6 low levels. The increased SIRT6 expression in
tumors versus normal controls was further verified by per-
forming a similar analysis on primary CD34+ blast cells
obtained from AML patients (n=200) collected at our
Hematology Unit, compared with BM as well as peripher-
al blood mononuclear cells (PBMCs) from healthy donors
(n=10). (Figure 1D) A subsequent investigation focusing
on molecular features showed that SIRT6 high levels were
significantly censured in FLT3-ITD mutant than in FLT3
wild type (P=0.034), otherwise no correlations were
observed between SIRT6 expression and further abnor-
malities including NPM1, BAALC and WT1 (Online
Supplementary Figure S1B). Among these 200 AML
patients, detailed survival information was available for
100 cases. As a result, we retrospectively analyzed the
prognostic significance of baseline SIRT6 expression from
BM aspirate samples on OS. Results show a statistically
significant inverse correlation between SIRT6 levels and
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OS, with high SIRT6 expression associated with shorter
survival rates than low expression (median survival 16 vs.
32 months; P=0.025) (Figure 1E). These results were also
observed by analyzing other publicly available AML
patient data sets,27 which confirmed the higher SIRT6
expression in tumors as well as its prognostic significance
(Online Supplementary Figure S2A and B). Taken together,
our data suggest SIRT6 plays a role in the pathogenesis of
AML, and also provide a rationale for its targeting.
SIRT6 controls AML cells proliferation and makes them
vulnerable to DNA-Damage Agents
To further elucidate the possible oncogenic role of
SIRT6 in AML, we investigated the effect of its genetic
depletion by employing a lentiviral-mediated long-term
gene knockdown with two shRNA constructs targeting
SIRT6 (Figure 2A). We chose two AML cell lines with
robust SIRT6 expression and the role of SIRT6 in cell via-
bility and proliferation was assessed. Surprisingly, intro-
duction of SIRT6-targeted shRNA induced a significant
increase in cell numbers and cell-cycle progression; these
were proportional to the reduction in protein levels (Figure
2A and B); while SIRT6 overexpression did not affect cell
count, due to the high SIRT6 levels at baseline (data not
shown). These findings, as already observed in MM and in
various solid tumors, are likely to account for the discrep-
ancies in the tumor burden, but clearly contrast with
SIRT6 overexpression in AML patients.15,28 Such paradox-
ical behavior prompted us to hypothesize a tumor-specific
role for this NAD+-dependent histone deacetylase.
As SIRT6 has been found to play a key role in mediating
DNA repair mechanisms,22,29-32 we investigated whether it
acts as genome-guardian also in AML blasts. SIRT6-
depleted cell lysates subjected to western blot analysis,
showed an increased γ-H2A.X staining, suggesting that
downregulation of SIRT6 expression enhances instability
of AML cells (Figure 2C and Online Supplementary Figure
S3) Importantly, these changes were not associated with
DNA response activation, since pATM, pATR, pCHK1
and pCHK2 were almost unchanged after SIRT6 silencing.
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Figure 1. SIRT6 is highly enriched in acute myeloid leukemia (AML) and its expression confers poor prognosis. (A) Protein lysates from a panel of AML cell lines
(left), primary patient-derived AML cultures or normal peripheral blood mononuclear cells (PBMCs) (right) were analyzed for SIRT6 expression by Western blot. GAPDH
was used as loading control. The quantification of SIRT6/GAPDH ratios is shown below. One experiment of two is shown. (B) Six AML cell lines were analyzed for
SIRT6 (green) by immunofluorescence. 4′,6-diamidino-2-phenylindole nuclear stain is shown in blue. Original magnification x20. (C) Box plot distributions of SIRT6
gene expression levels in normal hematopoietic cells from healthy donors and leukemic CD34+ blasts from AML patients (n=300), combining data from GSE1159,
GSE9476 and GSE30377 (using the probe set 219613_s_at). Normal hematopoietic samples included CD34+ selected cells [n=18: 8 from bone marrow (BM) and
10 from PB], CD34+ CD38– cells (n=10), unselected bone marrows (n=10), and unselected peripheral blood (n=6). Numbers below the graph are the number of sam-
ples per group. ns: not significant; **P<0.05; ***P<0.001 [one-way analysis of variance (ANOVA) with expression data log2 transformed]. (D) Increased SIRT6 mRNA
expression is observed in AML patients (CD34+ blast cells) relative to normal controls (CD34+ cells collected from PB or BM of healthy donors; **=0.006; *P=0.02,
unpaired t-test). GAPDH mRNA expression was used as an internal control. (E) Survival curves relative to SIRT6 expression in 100 individuals affected by AML diag-
nosed at our clinic. The patient group with higher SIRT6 expression (red line) had shorter overall survival than the patient cohort with lower SIRT6 expression (blue
line) (log rank test). Median SIRT6 mRNA value was used to divide AML patients.
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Similarly, replicative stress markers, including RAD51,
resulted unaffected by gene-knockdown in AML cells
(Figure 2C and Online Supplementary Figure S3). Overall,
these data indicate that SIRT6 depletion freezes DNA
repair mechanisms, which in turn leads to greater damage.
Lack of DNA repair efficiency sensitizes cancer cells to
DNA damaging agents (DDAs).33 Based on the observa-
tion that SIRT6 affects such mechanisms in AML, we
hypothesized that cells depleted of SIRT6 would be more
sensitive to the genotoxic agents DNR and Ara-C. We
therefore incubated SIRT6 depleted cells with clinically
relevant concentrations of either agents and assessed their
viability. Significantly more cytotoxicity was observed in
the absence of SIRT6 compared with scramble control
transfectants (Figure 2D). Consistent with these data, the
SIRT6 chemical inhibitor compound 134,35 was also found
to sensitize cell lines as well as primary AML cells to
DDAs (Figure 2E and F). Together, these results are consis-
tent with a leading role played by SIRT6 in regulating
AML cell sensitivity to chemotherapy.
SIRT6 loss affects ATM/CHK2 pathway, as well as
recruitment of repair factors to sites of DNA damage
As SIRT6-depleted cells are more sensitive to genotoxic
stress due to failure of DNA repair mechanisms, we next
measured levels of proteins mediating DNA DSBs
response after SIRT6 silencing. Although SIRT6 depletion
did not affect the protein level of ATM, CHK2 or RPA,
after DDAs treatment it markedly diminished their func-
tional activity. Specifically, in scramble control, DDAs
treatment induced RPA phosphorylation on Ser4 and Ser8,
as well as increased ATM and CHK2 phosphorylation
together with accumulation of lower-molecular-weight
protein γH2AX. DDAs treatment did not induce the same
effects (in term of phosphorylation of CHK2, RPA32, and
ATM) in SIRT6-knockdown cells. Similarly, the increase in
γH2AX level was more pronounced in SIRT6-depleted
OCI-AML2 and OCI-AML3 cells (Figure 3A and Online
Supplementary Figure S4). Overall, these observations iden-
tify a crucial role of SIRT6 in preserving genome integrity
of AML cells through promotion of DNA repair mecha-
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Figure 2. SIRT6 affects proliferation and vulnerability to DNA-damage agents in acute myeloid leukemia (AML) cells. (A) SIRT6 silencing in THP-1 and U937 cells
using a lentiviral delivery system. (Left) Western blot analysis of pGIPz-infected cells after 48 hours (h) of selection with 1 μg mL-1 puromycin. (Center) Cell numbers
evaluated by cell counting with trypan blue exclusion. (Right) AML-engineered cells were assessed for cell number and (B) cell-cycle progression. All data throughout
the panel are shown as mean±Standard Deviation (s.d.) of triplicates. ns: not significant; *P<0.01; **P<0.001, Student t-test. (C) Representative western blots
showing DDR pathway deregulation in THP-1 cells depleted of SIRT6 compared with control. GAPDH was used as loading control. One representative blot of two is
shown. (D) OCI-AML-2 and OCI-AML-3 cells were transduced with a scrambled shRNA (CTR) or with an anti-SIRT6 shRNA (#911). Cells were used for immunoblotting
detection of SIRT6 or γ-tubulin expression (top) or in viability experiments. For the latter, 2x104 cells/well were plated in 96-well plates and incubated for 48 hours
(h) with or without DNR or ARA-C at the indicated concentration. Thereafter, dead cells were detected by propidium iodide staining and flow cytometry. 2x104 OCI-
AML2 (E) and primary AML (F) cells/well were plated in 96-well plates and incubated for 72 h with (w) / or without (w/o) DNR/ARA-C (at the indicated concentration)
w / or w/o compound 1, as in Sociali et al.34 Thereafter, dead cells were detected by propidium iodide staining and flow cytometry. *0.04<P<0.01;
**0.009<P<0.001; ***<0.0001.
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nisms. Next, we asked whether SIRT6 also mediates the
recruitment of DNA repair factors to damage sites, which
represents an attempt to preserve genomic integrity. We
employed immunofluorescence to measure ability of
AML cells expressing SIRT6 shRNA to recruit repair fac-
tors, including 53BP1, Rad51, RPA and γH2AX, to the
sites of DNA damage following DDAs treatment.
Genotoxic stress resulted in increased γH2AX foci forma-
tion as well as impaired Rad51, pRPA and 53BP1 foci for-
mation in SIRT6-knockdown compared with SIRT6-wt
AML cells (Figure 3B-D). Therefore, the simultaneous
presence of increased DNA damage and decreased DNA
DSBs repair explains the observed hypersensitivity of
these cells to DDAs.
SIRT6 maintains genome integrity by deacetylation of
DNA-PKcs and CtIP in AML cells
To gain insights into specific function of SIRT6 in the
context of DNA damage to AML cells, we characterized
SIRT6-interacting proteins.30,36,37 GFP-tagged SIRT6 was
expressed in OCI-AML3 cells and then immunoprecipi-
tated with anti-GFP antibody. Western blot analysis
revealed that DNA-PKcs and CtIP were enriched in the
GFP-SIRT6 immunoprecipitates (IPs), mainly after DDAs
treatment. Importantly, SIRT6 inhibition by compound 1
heavily reduced levels of both proteins, also in the pres-
ence of genotoxic stress (Figure 4A).  Other SIRTs family
proteins, such as SIRT1, did not associate with GFP-
SIRT6 under these conditions, validating the specificity of
the assay. Analysis of endogenous SIRT6 IPs confirmed
this association, as well as its resistance to ethidium bro-
mide, indicating that it is not due to DNA bridging (Figure
4B and Online Supplementary Figure S5). Our data, there-
fore, indicate that SIRT6 interacts physically with DNA-
PKcs and CtIP in AML cells, and that this interaction
increases rapidly upon genotoxic stress. Since SIRT6 is a
histone deacetylase, we next tested whether acetylation
status of interacting proteins was affected by SIRT6
depletion. Each endogenous protein was pulled down
separately after treatment with DDAs in both SIRT6-wt
and SIRT6-KD AML cells. Although we readily detected
acetylation of DNA-PKcs as well as CtIP in SIRT6 wild-
type cells, their acetylation was abrogated after DNR and
Ara-C treatment. In contrast, DNA damage-induced
deacetylation of these proteins was totally abolished in
SIRT6-depleted cells (Figure 4C and Online Supplementary
Figure S6).  These data suggest that DNA-PKcs and CtIP
are constitutively acetylated in AML cells, and are
deacetylated by SIRT6 following genotoxic stimuli, there-
by promoting DNA damage repair. This observation was
further confirmed by treating AML cells over-expressing
human SIRT6(H133Y) catalytic mutant with increased
doses of DDAs. DDAs treatment resulted in a more pro-
nounced anti-tumor effect in AML cells over-expressing
A. Cagnetta et al.
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Figure 3. SIRT6 affects the ATM/CHK2 pathway, as well as recruitment of repair factors to sites of DNA damage in acute myeloid leukemia (AML) cells. (A) Indicated
AML cells were engineered to express an anti-SIRT6 shRNA (#911). Next, cells were incubated for 3 hours (h) with (w) or without (w/o) DNR (0.1 uM), or Ara-C (1
uM). Subsequently, total and phosphorylated ATM, Chk2, and RPA as well as γH2AX levels were detected by immunoblotting. Detection of Rad51 and γH2AX (B), pRPA
(C), 53BP1 (D), and DAPI was measured by confocal microscopy in OCI-AML2 cells expressing shRNA (clone #911) targeting SIRT6 or control and cultured with or
without treatment with Ara-C (1 μM) or DNR (0.1 μM) for 1 h (magnification x40). Each panel includes representative foci-containing cells graph, over three experi-
ments. *0.04<P<0.01; **0.009<P<0.001.
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the catalytically inactive mutant than the wild-type form
of SIRT6 (Figure 4D), indicating that enzymatic activity is
required for SIRT6 to maintain genomic stability of AML
cells. 
Ongoing DNA damage is associated with intense
replicative stress and high SIRT6 expression in AML
cells
Several studies have recently demonstrated a pervasive
dysregulation of genomic stability in several cancers,
including AML.8,38 To explore whether observed high
SIRT6 expression was related to the constitutive DNA
damage and intense replicative stress observed in AML
cells, we used a chromosomal instability signature
(CIN)16  to categorize AML cell lines included in a pub-
lished dataset (GSE59808). A subset of approximately
40% AML cell lines demonstrated overexpression of
probe sets belonging to CIN-signature (Figure 5A). To
confirm this finding, we next explored a panel of AML
cell lines together with primary tumor cells. Six of 9 AML
cell lines, as well as primary cells derived from 10 AML
patients, showed high γ-H2A.X staining (Figure  5B and
C) as well as activated DDR (Figure 5D). Remarkably, this
pattern was absent in normal PBMCs derived from
healthy individuals (Figure 5C), as already reported.39
Thus, such ongoing DNA damage observed in tumor cells
did not induce an extensive cell death under basal condi-
tions, suggesting existence of alternative mechanisms to
escape apoptotic cell death triggered in normal cells.
We had previously reported that SIRT6 preserves DNA
integrity in MM cells.15 To investigate whether such
deacetylase affects instability also in AML cells, we cate-
gorized leukemia cell lines included in GSE59808 accord-
ing to their SIRT6 expression levels. AML cell lines with
high CIN-signature exhibited greater SIRT6 mRNA levels
(P=0.01) (Figure 5E). As a measure of specificity of this
effect, we assessed gene expression profiles of AML cells
based on their SIRT6 levels using Gene Set Enrichment
Analysis.40 Remarkably, the gene expression profile
defined by Carter et al.16 significantly correlates with
SIRT6 expression in AML cells (P=0.02) (Figure 5F). In
parallel, analysis of the entire set of transcription target
gene signatures available from the Molecular Signatures
Database (MSigDB) showed gene sets included in DNA
replication and the cell-cycle regulatory gene pathway as
also being significantly deregulated in these cells (data not
shown), suggesting that SIRT6 drives DNA damage and
activation of DNA damage response also in AML cells.
AML patients with SIRT6 overexpression show features
of genomic instability and poor prognosis
We next examined whether the broad DNA damage
observed in AML patient-derived cells is also associated
with SIRT6 mRNA levels. To this end, we probed sam-
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Figure 4. SIRT6 depletion/inhibition sensitizes acute myeloid leukemia (AML) cells to genotoxic agents by disrupting DNA repair machinery. (A) OCI-AML2 cells
were engineered to express a GFP-tagged SIRT6. Cells were stimulated with compound 1, DNR (0.1 uM), or Ara-C (1 uM) for three hours (h). Thereafter, cells were
used for protein lysate generation. SIRT6 in the different samples was co-immunoprecipitated using an anti-GFP antibody. Finally, GFP, CtIP, DNA-PKcs and SIRT1 lev-
els were detected by immunoblotting. (B) OCI-AML2 cells were stimulated with compound 1, with (w) / or without (w/o) DNR (0.1 uM) for 3 h. Thereafter, cells were
used for protein lysate generation. Endogenous SIRT6 in the different samples was immunoprecipitated using an anti-SIRT6 antibody and CtIP, DNA-PKcs, SIRT6,
and SIRT1 levels were detected by immunoblotting. (C) OCI-AML2 engineered to express an shRNAs targeting SIRT6 (#911) were stimulated w / or w/o DNR (0.1
uM), or Ara-C (1 uM) for 3 h. CtIP (top) and DNA-PKcs (bottom) were immunoprecipitated and CtIP, DNA-PKcs, acetylated proteins (pan-acetyl-antibody) and γ-tubulin
were detected by immunoblotting. (D) Viability assays after Ara-C (left) or DNR (right) treatment of OCI-AML2 non-transfected cells, as well as in OCI-AML2 cells over-
expressing SIRT6 wild-type or mutant (H133Y). *P=0.02; **P<0.001.
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Figure 5. Ongoing DNA damage and high CIN signature are associated with intense replicative stress and SIRT6 overexpression in acute myeloid leukemia (AML)
cells. (A) Expression levels in a panel of 32 human AML cell lines for the probe sets corresponding to the chromosomal instability signature described by Carter et
al.16 using GSE59808. Red: gene expression over the median; blue: expression under the media. (B) Immunofluorescence staining of γ-H2A.X in AML cell lines and
primary tumor cells; magnification x40. (C) Western blot analysis (1 representative blot of 3) of γ-H2A.X in AML cell lines (top), AML patients’ cells, and peripheral
blood mononuclear cells (PBMCs) from healthy donors (bottom). GAPDH, glyceraldehyde 3-phosphate dehydrogenase. (D) 53BP1 and RAD51 number of foci in a
panel of AML cells presenting with high (red bracket) and low (blue bracket) DNA damage. (E) SIRT6 expression was compared to CIN signature among AML cell lines
in the GSE59808 data set; *P=0.04. (F) GSEA enrichment profile for AML cell lines (included in GSE59808) divided in high and low SIRT6 expression groups of chro-
mosomal instability signature, as reported by Carter et al.16 The analysis pointed to an association between high SIRT6 levels and CIN in AML cells.
Figure 6. High CIN gene expression signature confers poor prognosis in acute myeloid leukemia (AML) and correlates with SIRT6 expression. (A) Heat map showing
CIN signature in 1157 AML patients compared to CD34+ cells derived from healthy individuals (GSE1159, GSE7186, GSE425, GSE12417 and GSE37642). Red: gene
expression over the median; blue: gene expression under the media. (B) Expression levels for the probe sets corresponding to the chromosomal instability signature
using GEP data of 524 AML patients (GSE14468). (C) Kaplan-Meier survival curves of AML patients showed in (B) based on their CIN gene expression signature. (D)
GSEA enrichment profiles for AML patients included in GSE14468, divided into high and low SIRT6 expression groups of CIN signature as described by Carter et al.16
The analysis pointed to an association between high SIRT6 levels and CIN in AML cells. (E) SIRT6 expression was compared to CIN signature in AML patients
described in the GSE14468 data set. **P=0.001; ****P=0.0001.
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ples from 5 data sets, including tumor and CD34+ cells
from healthy donors (GSE1159, GSE7186, GSE425,
GSE12417 and GSE37642), for CIN gene expression sig-
nature. This analysis sharply divided samples into two
groups, with AML patients over-expressing probe sets
belonging to CIN signature compared with cells derived
from healthy individuals (Figure 6A). To further charac-
terize these data, we next investigated a publically avail-
able data set of 524 cases of de novo AML,41  observing that
tumor samples can be split up into three groups according
to the expression of genes included in CIN signature: low,
intermediate and high (Figure 6B). Importantly, this
arrangement did not overlap with other features, includ-
ing cytogenetic abnormalities and FLT3 mutations (data
not shown). Next, we analyzed the prognostic significance
of these findings, observing that patients displaying high-
er CIN signature demonstrated poor prognosis compared
with remaining patients (P<0.001) (Figure 6C). Finally, we
analyzed these AML patients using GSEA. As observed in
AML cell lines, this analysis revealed that CIN signature
was the most significantly altered pathway measured in
patients classified on the basis of their SIRT6 expression
level [P=0.03, false discovery rate (FDR)=0.04] (Figure
6D). The DNA repair pathway and the BRCAness signa-
ture42 also differed in these patient subgroups (Online
Supplementary Figure S7A and B). In line with these data,
higher SIRT6 levels were observed in patients with high
CIN signature than those with intermediate or low SIRT6
expression level (Figure 6E). Taken together our results
suggest a link between SIRT6 and genomic instability
also in AML patient-derived samples, justifying the high-
est SIRT6 levels observed in more aggressive disease sub-
types.
SIRT6 inhibition makes AML blasts more sensitive 
to DNR treatment in NSG mice 
To assess whether the biological results observed in
vitro also occur in vivo, we used two different xenotrans-
plant mouse models of AML. First, U937 scramble or
SIRT6-KD stably transduced cells were injected subcuta-
neously into NSG mice (n=20). After tumor engraftment,
mice (n=5) of each group were randomly assigned to
receive either 3 mg/kg of DNR administered intraperi-
toneally (at day 1 and 5) or vehicle control.15 As in the in
vitro setting, SIRT6 depletion made AML cells more sen-
sitive to genotoxic agents, with a significant reduction of
tumor growth in mice bearing these cells compared with
tumors induced by AML cells carrying normal SIRT6 lev-
els. Indeed, at day 30 after tumor injection, mean tumor
volume was 60 versus 40 mm2, respectively (P=0.03)
(Figure 7A). 
In a second in vivo model, we intravenously injected
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Figure 7. SIRT6 inhibition makes acute myeloid leukemia (AML) blasts more sensitive to DNR treatment in NSG mice. (A) Growth of U937 control and SIRT6-deplet-
ed xenografts in mice treated with vehicle or DNR (3 mg/kg i.p. day 1 and day +4) at day 20 after tumor engraftment. *P=0.036. Data are mean tumor
volume±Standard Deviation (s.d.). (B) 1x106 of scramble or shSIRT6-expressing HL-60 cells were engrafted into NSG mice (n=20) by tail-vein injection. Once a sys-
temic xenograft was confirmed, mice were randomized to receive DNR (1.5 mg/kg for 3 days) (treated group) or vehicle (control group). Histogram represents per-
centage of human CD45+ cells in mice, at day 31 post engraftment. Data are represented as mean±Standard Error of Mean (SEM); **P=0.006. (C) Representative
flow cytometric dot plots representing tumor engraftment evaluated at day 40 post injection. (D) Kaplan-Meier survival plot showing median survival of mice injected
with tumors with (w)  / without (wo) SIRT6 before and after treatment with vehicle or DNR.
A B
C D
human HL-60 cells, scramble or SIRT6 shRNA-trans-
duced, into NSG mice (n =20;  5 mice per condition). Once
a systemic xenograft was confirmed (>0.1% in peripheral
blood of mice) the treatment regimen was initiated (1.5
mg/kg of DNR administered intraperitoneally, for 3 days,
or vehicle control). At day 31 after cell transfer, flow
cytometry evaluation of the circulating human CD45+
cells in the murine PB was performed to assess AML
engraftment. This analysis revealed a significantly lower
leukemia burden after DNR-treatment than vehicle
(Figure 7B), with SIRT6 depletion making these cells more
sensitive to chemotherapy (% of human engraftment:
0.9±0.1% and 0.16±0.01%, respectively; P=0.006), as
observed in vitro. Tumor cell engraftment was measured
also at day 40 and results showed that SIRT6-depleted
treated mice had significantly fewer tumor cells com-
pared with relative control (Figure 7C). Furthermore,
Kaplan-Meier analyses indicated that DNR-treated mice
injected with SIRT6 survived significantly longer than
those bearing tumors with normal SIRT6 levels (56 vs. 39
days; P=0.004) (Figure 7D). Overall these data show that
AML blasts depleted of SIRT6 are more sensitive to
DDAs agents also in an in vivo environment, suggesting,
therefore, evaluation of SIRT6 inhibition to be a novel
strategy to enhance DDAs sensitivity in AML patients.
Discussion
The efficiency of DNA-repair and DNA damage-
response pathways, affects both cancer susceptibility and
responses to genotoxic agent-based therapies.33 As a
result, synthetic lethal approaches to specifically kill can-
cer cells, that are dependent on compensatory DNA
repair pathways, are emerging as a vulnerability that can
be therapeutically targeted.39,43-45 In this context, we have
recently shown that the chromatin-bound factor, SIRT6,
safeguards the genome of MM cells.15 Here, we further
extend these observations to AML cells and demonstrate
that SIRT6 controls leukemogenesis and tumor growth
by struggling with their instability. Indeed, we show that
defects in SIRT6 expression or activity sensitize AML
cells to genotoxic agents, leading to a significant reduc-
tion in blast-cell count, and to prolonged survival in AML
mice models. Co-IP experiments have also demonstrated
that SIRT6 deacetylates DNA-PKcs and CtIP, resulting in
efficient DNA repair mechanisms and integrity of AML
cells. In contrast, loss of SIRT6 enzymatic activity
enhances instability, which in turn sensitizes leukemia
cells to DDAs. Overall, our data suggest an innovative
strategy to enhance efficacy of chemotherapy, which still
remain the backbone for treatment, in AML. Additionally,
based on low SIRT6 levels detected in normal CD34+
hematopoietic progenitors, a favorable therapeutic index
of such an approach is also warranted. Genomic instabil-
ity is one of the distinctive markers of tumor cells provid-
ing them with additional capabilities crucial for tumorige-
nesis.46-50 In hematologic cancers, the relevance of such
features, and the mechanisms underlying instability are
largely unknown.15,30,51-57 Based on our data, we assume
that pervasive DNA damage observed in AML cells is
reliant on genes such as SIRT6 that, when disrupted, lead
to further instability.58,59 The prominent role exerted by
SIRT6 on leukemogenesis is reinforced by its prognostic
relevance, as observed in primary AML samples. Indeed,
SIRT6 overexpression is associated with greater instabili-
ty and a worse prognosis. As a result, genetic inactivation
of this chromatin remodeler triggers growth advantage
and DNA repair weakening that in turn cause greater
DDAs sensitivity. A comprehensive genomic analysis
revealed that AML patients harbor several genetic alter-
ations, including 
FLT3-ITD which primes leukemic cells to become geno-
toxic stress-induced.12 Here we observed higher SIRT6
mRNA expression levels in AML patients carrying FLT3-
ITD mutant, providing further evidence for a direct link
between SIRT6 and genomic instability in AML.
Nevertheless, these effects were not related to other spe-
cific genetic makeup, suggesting that SIRT6 acts on the
genomic stability of AML regardless of its specific
genomic landscape.
As the cancer genome is itself reflective of phenotypic
properties, specific gene signatures have been used to pre-
dict clinical outcome and identify prognostically relevant
features in different cancer subtypes.60,61 Similarly, meas-
urement of the degree of genomic instability, by leverag-
ing specific gene signature, provides a valuable tool for
prognostic stratification.62 Based on our data, here we
asked whether consequences of aberrant DNA repair are
reflected in genomic features, and how these events are
associated with SIRT6 expression levels in AML cells.
Therefore, we analyzed published databases for abnor-
mal expression of genes belonging to chromosomal insta-
bility signature,14 recently identified as instability bio-
marker.43 The CIN-based stratification highly correlated
with SIRT6 mRNA levels (Figure 6); greater instability
was observed in patients harboring the highest SIRT6 lev-
els which results in poor prognosis.  Thus, our data iden-
tify SIRT6 as a valuable feature to segregate AML patients
into distinct molecular and biological classes.
Besides SIRT6, also SIRT1 promotes genomic integrity
of tumor cells, proposing an over-lapping function.52,63 In
such a scenario, a broad gene expression analysis of SIRTs
family members revealed SIRT6 and SIRT1 to be at the
top of the list, thus supporting the crucial role of these
two proteins for AML cells (Online Supplementary Figure
S8A and B). SIRT6 is a chromatin-bound deacetylase that
participates in DNA double-strand break repair by affect-
ing activity of several proteins, including CtIP, PARP1,
DNA-PK complex and SNF2H at DNA damage
sites.30,32,36,56 Here we show that, after genotoxic stress,
AML cells rapidly recruit SIRT6 to DNA damaged sites
where it deacetylates and promotes activity of DNA-PKcs
and CtIP. In contrast, compromising SIRT6 activity
decreases repair mechanisms, resulting in greater DDAs
cytotoxicity both in vitro and in murine xenograft models
of human AML. 
In summary, among the potential mechanisms that
could cause instability, the disruption of the DNA repair
complex is an intriguing avenue of research that should
be pursued in anti-cancer therapies to increase the activi-
ty of currently used therapeutics. While an analysis of
larger cohorts of patients may yet identify additional data
on the specific impact of SIRT6 on genomic instability,
here we identify such deacetylase action as a vulnerabili-
ty to be exploited in developing future intervention
strategies, and speculate as to its role as a surrogate genet-
ic marker for instability in AML patients. Overall, our
study provides proof-of-concept that depletion of SIRT6
represents a novel strategy to selectively target AML cells
A. Cagnetta et al.
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